MBRX — Moleculin Biotech Share News
0.000.00%
Last trade - 00:00Brief: Moleculin Biotech Files Prospectus For Resale Of Common Stock - SEC Filing
Brief: Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Brief: Moleculin Biotech Inc - Completion Of Its Phase 1B/2 (Mb-106) Clinical Trial Evaluating Annamycin In Combination With Cytarabine
Moleculin Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Moleculin Biotech Receives Notice Of Intent To Grant New European Patent For Annamycin
Brief: Moleculin Biotech Receives Nasdaq Deficiency Letter For Bid Price - SEC Filing
Moleculin Biotech Inc reports results for the quarter ended March 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global
U.S. STOCKS ON THE MOVE-Fox, Manpower Group, US chipmakers
Brief: Moleculin Receives European Medicines Agency Approval To Expand Phase 3 Miracle Clinical Trial
Moleculin Biotech rises after EMA approves late-stage study of cancer therapy
Moleculin Biotech Inc expected to post a loss of 56 cents a share - Earnings Preview
Moleculin Biotech Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Moleculin Biotech Granted Two Additional U.S. Patents For Annamycin
Brief: Moleculin Announces New Pre-Clinical Data For Annamycin
Brief: Moleculin Announces Acceptance Of Abstract To Be Presented At The American Association For Cancer Research Annual Meeting 2025
Brief: Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial
Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary
Moleculin Biotech Inc expected to post a loss of $1.28 a share - Earnings Preview